<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04797962</url>
  </required_header>
  <id_info>
    <org_study_id>20-2236</org_study_id>
    <secondary_id>R01CE00300</secondary_id>
    <nct_id>NCT04797962</nct_id>
  </id_info>
  <brief_title>Connection, Navigation, Engagement in Care and Treatment for Opioid Use Disorder</brief_title>
  <acronym>ConNECT</acronym>
  <official_title>Linkage Navigation to Enhance Initiation and Engagement in Treatment for Opioid Use Disorder to Prevent Overdose</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Denver Health and Hospital Authority</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centers for Disease Control and Prevention</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Denver Health and Hospital Authority</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overarching goal of the study is to develop, pilot, and evaluate an intervention that&#xD;
      aims to retain patients who initiate buprenorphine at Denver Health in ongoing treatment for&#xD;
      opioid use disorder.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Initiating patients identified with opioid use disorder in hospital settings onto&#xD;
      buprenorphine is a relatively new strategy to prevent overdose. While the literature is&#xD;
      beginning to amass showing the effectiveness of this strategy for initiating people into&#xD;
      treatment, a dearth of data to describe how well people are maintained in treatment remains.&#xD;
      The current research project aims to 1) develop an intervention to enhance engagement and&#xD;
      retention in treatment for individuals with opioid use disorder who initiate buprenorphine at&#xD;
      Denver Health and 2) assess acceptability, feasibility, and initial efficacy of an&#xD;
      intervention to enhance engagement and retention in treatment for individuals with opioid&#xD;
      disorder compared to usual care.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 30, 2021</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Retention in treatment at 90 days</measure>
    <time_frame>90 days from treatment initiation</time_frame>
    <description>Defined by proportion of participants retained in care at 90 days, as measured by the total number of intakes where patient has continued to be engaged in medication assisted treatment at 90 days from start of treatment divided by the total number of intakes where patients linked to follow up dosing or prescription, for each arm.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Opioid-use Disorder</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>dedicated case management</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>usual care</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Case management</intervention_name>
    <description>dedicated case management to address social support needs</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 years and older&#xD;
&#xD;
          -  inducted onto buprenorphine at Denver Health&#xD;
&#xD;
          -  successfully completed an intake visit at Denver Health's Outpatient Behavioral Health&#xD;
             Services clinic.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  unable to provide informed consent&#xD;
&#xD;
          -  unable to provide detailed contact information&#xD;
&#xD;
          -  previously enrolled in the current study&#xD;
&#xD;
          -  pregnant women will be excluded given that they are a priority treatment population&#xD;
             and receive special services&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alia Al-Tayyib, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Denver Health</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Melissa Hordes, MPH</last_name>
    <phone>303-602-4461</phone>
    <email>melissa.hordes@dhha.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Denver Health</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Hordes, MPH</last_name>
      <phone>303-602-4461</phone>
      <email>melissa.hordes@dhha.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>March 10, 2021</study_first_submitted>
  <study_first_submitted_qc>March 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 15, 2021</study_first_posted>
  <last_update_submitted>April 2, 2021</last_update_submitted>
  <last_update_submitted_qc>April 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Denver Health and Hospital Authority</investigator_affiliation>
    <investigator_full_name>Alia Al-Tayyib</investigator_full_name>
    <investigator_title>Associate Research Scientist</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Opioid-Related Disorders</mesh_term>
    <mesh_term>Substance-Related Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

